Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL661910 | 0.65 | — | — | |
| Phosphoric Acid SCHEMBL14890175 | 0.64 | CA2 (0.46) | LAP3CA2 | |
| Phosphoric Acid SCHEMBL28943185 | 0.64 | CA2 (0.46) | LAP3CA2 | |
| Phosphoric Acid SCHEMBL27548563 | 0.61 | ALDH1A1 (0.50) | LAP3CA2 | |
| Phosphoric Acid SCHEMBL28541600 | 0.61 | — | — | |
| Phosphoric Acid SCHEMBL9258890 | 0.61 | CA2 (0.43) | CA2 | |
| Phosphoric Acid SCHEMBL27734049 | 0.61 | CA2 (0.35) | LAP3CA2 | |
| Tetramethylammonium Ion SCHEMBL10737257 | 0.60 | CA2 (0.50) | LAP3CA2 | |
| Phosphoric Acid SCHEMBL571124 | 0.60 | CA2 (0.50) | LAP3CA2 | |
| Phosphoric Acid SCHEMBL5901916 | 0.60 | CA2 (0.50) | LAP3CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170210775-A1 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | JINA PHARMACEUTICALS, INC. | 2017-07-27 | — | — | US | claimed |
| US-9637515-B2 | Guggulphospholipid methods and compositions | JINA PHARMACEUTICALS, INC. (US) | 2017-05-02 | — | — | US | claimed |
| EP-2088865-B1 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | JINA PHARMACEUTICALS INC (US) | 2015-10-21 | — | — | EP | claimed |
| US-20100151002-A1 | Guggulphospholipid Methods and Compositions | JINA PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | claimed |
| US-20250243540-A1 | PROBE RELATED REAGENTS AND METHODS | BRENTANO BIOTECHNOLOGY ASSOCIATES (US) | 2025-07-31 | — | — | US | disclosed |
| EP-4034131-A1 | DIASTEREOMERIC LINKING REAGENTS FOR NUCLEOTIDE PROBES | Brentano Biotechnology Associates (US) | 2022-08-03 | — | — | EP | disclosed |
| US-20220073546-A1 | DIASTEREOMERIC LINKING REAGENTS FOR NUCLEOTIDE PROBES | BRENTANO BIOTECHNOLOGY ASSOCIATES (US) | 2022-03-10 | — | — | US | disclosed |
| WO-2021061154-A1 | DIASTEREOMERIC LINKING REAGENTS FOR NUCLEOTIDE PROBES | BRENTANO BIOTECHNOLOGY ASSOCIATES (US) | 2021-04-01 | — | — | WO | disclosed |
| US-20170210775-A1 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | JINA PHARMACEUTICALS, INC. | 2017-07-27 | — | — | US | disclosed |
| US-9637515-B2 | Guggulphospholipid methods and compositions | JINA PHARMACEUTICALS, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| EP-2088865-B1 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | JINA PHARMACEUTICALS INC (US) | 2015-10-21 | — | — | EP | disclosed |
| US-7745614-B2 | Universal linker compositions for the release or transfer of chemical agents from a polynucleotide | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2010-06-29 | — | — | US | disclosed |
| EP-0313219-B1 | Non-nucleotide linking reagents for nucleotide probes | GEN PROBE INC (US) | 1996-05-08 | — | — | EP | disclosed |
| US-5324631-A | Spectrum analysis of amplified hybrid products produced by contacting various fluorescent-labelled primers with the genomic DNA, particularly that of plants | PIONEER HI-BRED INTERNATIONAL, INC. | 1994-06-28 | — | — | US | disclosed |
| US-5145842-A | Protein kinase c. modulators. d. | ALDER RESEARCH CENTER LIMITED PARTNERSHIP (US) | 1992-09-08 | — | — | US | disclosed |
| EP-0469042-A4 | NOVEL OLIGODEOXYNUCLEOTIDES WITH 5'-LINKED CHEMICAL GROUPS, METHOD OF PRODUCTION THEREOF AND USE THEREOF | US HEALTH (US) | 1992-07-01 | — | — | EP | disclosed |
| WO-1992002484-A1 | PROTEIN KINASE C MODULATORS WITH ANTI-INFLAMMATORY AND ANTIVIRAL ACTIVITY | ALDER RESEARCH CENTER LIMITED PARTNERSHIP (US) | 1992-02-20 | — | — | WO | disclosed |
| EP-0469042-A1 | NOVEL OLIGODEOXYNUCLEOTIDES WITH 5'-LINKED CHEMICAL GROUPS, METHOD OF PRODUCTION THEREOF AND USE THEREOF | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) | 1992-02-05 | — | — | EP | disclosed |
| WO-1990012802-A1 | NOVEL OLIGODEOXYNUCLEOTIDES WITH 5'-LINKED CHEMICAL GROUPS, METHOD OF PRODUCTION THEREOF AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) | 1990-11-01 | — | — | WO | disclosed |
| EP-0313219-A2 | Non-nucleotide linking reagents for nucleotide probes | GEN-PROBE INCORPORATED (US) | 1989-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100151002-A1 | Guggulphospholipid Methods and Compositions | SGMS2, SGMS1, PLA2G5 | LAP3 2784/4885CA2 4036/4885 |
| US-20170210775-A1 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | SGMS1, SGMS2, GGPS1 | LAP3 1757/4885CA2 2837/4885 |
| US-20250243540-A1 | PROBE RELATED REAGENTS AND METHODS | DNTT, NCL, NT5C3B | LAP3 1180/4885CA2 2855/4885 |
| US-20220073546-A1 | DIASTEREOMERIC LINKING REAGENTS FOR NUCLEOTIDE PROBES | NCL, PCNA, DNTT | LAP3 1845/4885CA2 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.